Drug Trial Radar · NCT04196101
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Last checked: Nov 19, 2026Latest source record: Oct 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Jan 22, 2020
Primary completion
Jan 4, 2022
Study completion Jan 4, 2022
Sponsor
- Lead sponsor
- Enanta Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP
- First posted
- Dec 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.
Conditions
- Respiratory Syncytial Virus
Interventions
EDP-938Drug
Four tablets daily for 5 days
PlaceboDrug
Four tablets daily for 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Symptom Score (TSS) Area Under the Curve (AUC)Time frame: Day 1 through Day 14
Locations
29 sites in 7 countries. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama
Cahaba Research Inc. - Birmingham
Pelham, Alabama
Saint Joseph's Clinical Research
Anaheim, California
Torrance Clinical Research Institute
Lomita, California
Miami Clinical Research - ClinEdge - PPDS
Miami, Florida
Pioneer Clinical Research LLC
Bellevue, Nebraska
Meridian Clinical Research
Norfolk, Nebraska
Clinical Research of South Nevada
Las Vegas, Nevada
Carolina Research Center
Shelby, North Carolina
PMG Research of Wilmington
Wilmington, North Carolina
Progressive Medicine of the Triad, LLC
Winston-Salem, North Carolina
FMC Science
Lampasas, Texas
Instituto Medico Platense
Buenos Aires, Argentina
Multiprofile Hospital for Active Treatment Puls
Blagoevgrad, Bulgaria
Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD
Haskovo, Bulgaria
Medical Center Zdrave-1 OOD
Kozloduy, Bulgaria
Medical Center Tara OOD
Veliko Tarnovo, Bulgaria
Diagnostic and Consulting Center Aleksandrovska EOOD
Sofia, Sofia-Grad, Bulgaria
Medical Center Hera
Sofia, Sofia-Grad, Bulgaria
Lakeland Clinical Trials - Waikato
Hamilton, New Zealand
Lakeland Clinical Trials
Rotorua, New Zealand
Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota
Ostróda, Poland
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z.o.o
Tarnów, Lesser Poland Voivodeship, Poland
Clinical Projects Research SA pty Ltd
Worcester, Western Cape, South Africa
City Outpatient Clinic #9
Kyiv, Ukraine
Medical Center of LLC Preventclinic
Kyiv, Ukraine
Limited Liability Company Medical Center Consilium Medical
Kyiv, Ukraine
Communal Non-Profit Enterprise City Clinical Hospital #1 of Ivano-Frankivsk City Council
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Municipal Enterprise The 1st City Clinical Hospital of Poltava City Council
Poltava, Poltava Oblast, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.